Exocrine Pancreatic Insufficiency - Pipeline Review, H1 2017

  • ID: 4311848
  • Report
  • 42 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Celleron Therapeutics Ltd
  • Cilian AG
  • MORE
Exocrine Pancreatic Insufficiency - Pipeline Review, H1 2017

Summary:

The latest Pharmaceutical and Healthcare disease pipeline guide Exocrine Pancreatic Insufficiency - Pipeline Review, H1 2017, provides an overview of the Exocrine Pancreatic Insufficiency (Gastrointestinal) pipeline landscape.

Exocrine pancreatic insufficiency (EPI) is a condition characterized by deficiency of the exocrine pancreatic enzymes, resulting in the inability to digest food properly, or maldigestion. Symptoms include diarrhea, loose, oily stools with unabsorbed fat (steatorrhea), vitamin deficiencies, loss of appetite, and unexplained weight loss. Treatment includes pancreatic enzyme replacement therapy (PERT) and lifestyle modifications.

Report Highlights:

The latest Pharmaceutical and Healthcare latest pipeline guide Exocrine Pancreatic Insufficiency - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Exocrine Pancreatic Insufficiency (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Exocrine Pancreatic Insufficiency (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Exocrine Pancreatic Insufficiency and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II and Preclinical stages are 1, 3 and 1 respectively.

Exocrine Pancreatic Insufficiency (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from our proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Exocrine Pancreatic Insufficiency (Gastrointestinal).
  • The pipeline guide reviews pipeline therapeutics for Exocrine Pancreatic Insufficiency (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Exocrine Pancreatic Insufficiency (Gastrointestinal) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Exocrine Pancreatic Insufficiency (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Exocrine Pancreatic Insufficiency (Gastrointestinal)
Reasons to Buy:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Exocrine Pancreatic Insufficiency (Gastrointestinal).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Exocrine Pancreatic Insufficiency (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Celleron Therapeutics Ltd
  • Cilian AG
  • MORE
  1. Introduction
  2. Exocrine Pancreatic Insufficiency - Overview
  3. Exocrine Pancreatic Insufficiency - Therapeutics Development
  4. Pipeline Overview
  5. Pipeline by Companies
  6. Products under Development by Companies
  7. Exocrine Pancreatic Insufficiency - Therapeutics Assessment
  8. Assessment by Target
  9. Assessment by Mechanism of Action
  10. Assessment by Route of Administration
  11. Assessment by Molecule Type
  12. Exocrine Pancreatic Insufficiency - Companies Involved in Therapeutics Development
  13. Anthera Pharmaceuticals Inc
  14. Celleron Therapeutics Ltd
  15. Cilian AG
  16. Laboratoires Mayoly Spindler SAS
  17. Nordmark Arzneimittel GmbH & Co KG
  18. Exocrine Pancreatic Insufficiency - Drug Profiles
  19. burlulipase - Drug Profile
  20. Product Description
  21. Mechanism Of Action
  22. R&D Progress
  23. Cilase - Drug Profile
  24. Product Description
  25. Mechanism Of Action
  26. R&D Progress
  27. CXD-101 - Drug Profile
  28. Product Description
  29. Mechanism Of Action
  30. R&D Progress
  31. liprotamase - Drug Profile
  32. Product Description
  33. Mechanism Of Action
  34. R&D Progress
  35. MS-1819 - Drug Profile
  36. Product Description
  37. Mechanism Of Action
  38. R&D Progress
  39. Exocrine Pancreatic Insufficiency - Dormant Projects
  40. Exocrine Pancreatic Insufficiency - Discontinued Products
  41. Exocrine Pancreatic Insufficiency - Product Development Milestones
  42. Featured News & Press Releases
  43. May 15, 2017: Anthera Announces First Patient Screened in RESULT Pivotal Phase 3 Clinical Study of Sollpura
  44. Apr 11, 2017: AzurRx Provides Update on MS1819 Phase II Trial
  45. Dec 21, 2016: AzurRx BioPharma Announces First Three Patients Included in Phase IIa Study with MS1819-SD for Endocrine Pancreatic Insufficiency
  46. Nov 17, 2016: AzurRx BioPharma and Mayoly-Spindler Announce Initiation of Phase II Clinical Trial of MS1819-SD for Exocrine Pancreatic Insufficiency in Chronic Pancreatitis Patients
  47. Jun 28, 2016: Anthera Provides Clinical Program Update for Sollpura
  48. Mar 19, 2015: Anthera Announces $3 Million Research Award from Cystic Fibrosis Foundation Therapeutics for Development of Sollpura - a Novel Enzyme Therapy
  49. Nov 20, 2014: Anthera and Patheon Sign Manufacturing Agreement for Liprotamase Phase III Registration Trial
  50. Aug 01, 2012: Cilian Receives €1m Grant For Development Of Cilase
  51. Apr 15, 2011: Lilly Receives Complete Response Letter From FDA For Liprotamase For Treatment Of Exocrine Pancreatic Insufficiency
  52. Jan 12, 2011: Lilly Announces FDA Panel Recommendation For Liprotamase
  53. Jun 22, 2010: Protea Biosciences And Mayoly-­Spindler Announce Human Clinical Trial For New Biopharmaceutical.
  54. Appendix
  55. Methodology
  56. Coverage
  57. Secondary Research
  58. Primary Research
  59. Expert Panel Validation
  60. Contact Us
  61. Disclaimer
List of Tables:
  1. Number of Products under Development for Exocrine Pancreatic Insufficiency, H1
  2. Number of Products under Development by Companies, H1
  3. Products under Development by Companies, H1
  4. Number of Products by Stage and Target, H1
  5. Number of Products by Stage and Mechanism of Action, H1
  6. Number of Products by Stage and Route of Administration, H1
  7. Number of Products by Stage and Molecule Type, H1
  8. Exocrine Pancreatic Insufficiency - Pipeline by Anthera Pharmaceuticals Inc, H1
  9. Exocrine Pancreatic Insufficiency - Pipeline by Celleron Therapeutics Ltd, H1
  10. Exocrine Pancreatic Insufficiency - Pipeline by Cilian AG, H1
  11. Exocrine Pancreatic Insufficiency - Pipeline by Laboratoires Mayoly Spindler SAS, H1
  12. Exocrine Pancreatic Insufficiency - Pipeline by Nordmark Arzneimittel GmbH & Co KG, H1
  13. Exocrine Pancreatic Insufficiency - Dormant Projects, H1
  14. Exocrine Pancreatic Insufficiency - Discontinued Products, H1
List of Figures:
  1. Number of Products under Development for Exocrine Pancreatic Insufficiency, H1
  2. Number of Products under Development by Companies, H1
  3. Number of Products by Targets, H1
  4. Number of Products by Stage and Targets, H1
  5. Number of Products by Mechanism of Actions, H1
  6. Number of Products by Stage and Mechanism of Actions, H1
  7. Number of Products by Stage and Routes of Administration, H1
  8. Number of Products by Molecule Types, H1
  9. Number of Products by Stage and Molecule Types, H1
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Anthera Pharmaceuticals Inc
  • Celleron Therapeutics Ltd
  • Cilian AG
  • Laboratoires Mayoly Spindler SAS
  • Nordmark Arzneimittel GmbH & Co KG
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll